(ENSG) The Ensign - Overview
Stock: Skilled Nursing, Senior Living, Rehabilitation
| Risk 5d forecast | |
|---|---|
| Volatility | 25.6% |
| Relative Tail Risk | -8.10% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.63 |
| Alpha | 46.66 |
| Character TTM | |
|---|---|
| Beta | 0.415 |
| Beta Downside | 0.228 |
| Drawdowns 3y | |
|---|---|
| Max DD | 23.49% |
| CAGR/Max DD | 1.36 |
EPS (Earnings per Share)
Revenue
Description: ENSG The Ensign January 07, 2026
The Ensign Group, Inc. (NASDAQ: ENSG) operates a network of skilled-nursing, senior-living, and rehabilitative facilities across 16 U.S. states, delivering both direct patient care (short- and long-term nursing, specialty services such as dialysis and ventilator management) and ancillary services (digital imaging, pharmacy, transportation). Its business is split between the Skilled Services segment, which provides the clinical and residential care, and the Standard Bearer segment, which generates lease income by renting post-acute care properties to other operators.
Key operating metrics show the company’s scale and financial health: as of FY 2023, ENSG reported approximately 6,200 licensed beds with an average occupancy rate of roughly 85%, and total revenue of $1.2 billion, reflecting a 5% year-over-year growth. EBITDA margins have hovered near 12%, while cash flow from operations remains positive, supporting ongoing capital expenditures and debt repayment. Sector-wide, the aging U.S. population and rising demand for post-acute care-driven by higher Medicare Advantage enrollment and tighter hospital discharge policies-are fundamental tailwinds for ENSG’s service lines.
For a deeper dive into ENSG’s valuation metrics, you might explore the analysis on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 344.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 2.74 > 1.0 |
| NWC/Revenue: 7.47% < 20% (prev 9.72%; Δ -2.25% < -1%) |
| CFO/TA 0.10 > 3% & CFO 564.3m > Net Income 344.0m |
| Net Debt (3.65b) to EBITDA (567.9m): 6.43 < 3 |
| Current Ratio: 1.42 > 1.5 & < 3 |
| Outstanding Shares: last quarter (59.3m) vs 12m ago 1.21% < -2% |
| Gross Margin: 13.74% > 18% (prev 0.16%; Δ 1359 % > 0.5%) |
| Asset Turnover: 99.84% > 50% (prev 91.24%; Δ 8.59% > 0%) |
| Interest Coverage Ratio: 58.04 > 6 (EBITDA TTM 567.9m / Interest Expense TTM 7.99m) |
Altman Z'' 2.69
| A: 0.07 (Total Current Assets 1.27b - Total Current Liabilities 894.3m) / Total Assets 5.46b |
| B: 0.32 (Retained Earnings 1.76b / Total Assets 5.46b) |
| C: 0.09 (EBIT TTM 463.6m / Avg Total Assets 5.07b) |
| D: 0.54 (Book Value of Equity 1.76b / Total Liabilities 3.23b) |
| Altman-Z'' Score: 2.69 = A |
Beneish M -2.89
| DSRI: 0.94 (Receivables 637.0m/569.9m, Revenue 5.06b/4.26b) |
| GMI: 1.14 (GM 13.74% / 15.67%) |
| AQI: 0.94 (AQ_t 0.07 / AQ_t-1 0.08) |
| SGI: 1.19 (Revenue 5.06b / 4.26b) |
| TATA: -0.04 (NI 344.0m - CFO 564.3m) / TA 5.46b) |
| Beneish M-Score: -2.89 (Cap -4..+1) = A |
What is the price of ENSG shares?
Over the past week, the price has changed by +17.47%, over one month by +15.39%, over three months by +12.39% and over the past year by +58.06%.
Is ENSG a buy, sell or hold?
- StrongBuy: 4
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ENSG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 217.2 | 6.5% |
| Analysts Target Price | 217.2 | 6.5% |
| ValueRay Target Price | 273.7 | 34.2% |
ENSG Fundamental Data Overview February 10, 2026
P/E Forward = 26.738
P/S = 2.2727
P/B = 5.1503
P/EG = 1.7802
Revenue TTM = 5.06b USD
EBIT TTM = 463.6m USD
EBITDA TTM = 567.9m USD
Long Term Debt = 137.5m USD (from longTermDebt, last quarter)
Short Term Debt = 119.0m USD (from shortTermDebt, last quarter)
Debt = 4.15b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.65b USD (from netDebt column, last quarter)
Enterprise Value = 15.08b USD (11.49b + Debt 4.15b - CCE 572.4m)
Interest Coverage Ratio = 58.04 (Ebit TTM 463.6m / Interest Expense TTM 7.99m)
EV/FCF = 40.67x (Enterprise Value 15.08b / FCF TTM 370.7m)
FCF Yield = 2.46% (FCF TTM 370.7m / Enterprise Value 15.08b)
FCF Margin = 7.33% (FCF TTM 370.7m / Revenue TTM 5.06b)
Net Margin = 6.80% (Net Income TTM 344.0m / Revenue TTM 5.06b)
Gross Margin = 13.74% ((Revenue TTM 5.06b - Cost of Revenue TTM 4.36b) / Revenue TTM)
Gross Margin QoQ = 8.67% (prev 14.67%)
Tobins Q-Ratio = 2.76 (Enterprise Value 15.08b / Total Assets 5.46b)
Interest Expense / Debt = 0.05% (Interest Expense 1.96m / Debt 4.15b)
Taxrate = 26.56% (34.5m / 130.1m)
NOPAT = 340.5m (EBIT 463.6m * (1 - 26.56%))
Current Ratio = 1.42 (Total Current Assets 1.27b / Total Current Liabilities 894.3m)
Debt / Equity = 1.86 (Debt 4.15b / totalStockholderEquity, last quarter 2.23b)
Debt / EBITDA = 6.43 (Net Debt 3.65b / EBITDA 567.9m)
Debt / FCF = 9.85 (Net Debt 3.65b / FCF TTM 370.7m)
Total Stockholder Equity = 2.07b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.79% (Net Income 344.0m / Total Assets 5.46b)
RoE = 16.58% (Net Income TTM 344.0m / Total Stockholder Equity 2.07b)
RoCE = 20.96% (EBIT 463.6m / Capital Employed (Equity 2.07b + L.T.Debt 137.5m))
RoIC = 15.36% (NOPAT 340.5m / Invested Capital 2.22b)
WACC = 5.47% (E(11.49b)/V(15.65b) * Re(7.44%) + D(4.15b)/V(15.65b) * Rd(0.05%) * (1-Tc(0.27)))
Discount Rate = 7.44% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 1.50%
[DCF Debug] Terminal Value 86.66% ; FCFF base≈298.0m ; Y1≈308.0m ; Y5≈348.3m
Fair Price DCF = 115.3 (EV 10.35b - Net Debt 3.65b = Equity 6.70b / Shares 58.1m; r=5.90% [WACC]; 5y FCF grow 3.44% → 2.90% )
EPS Correlation: 98.15 | EPS CAGR: 17.63% | SUE: 1.39 | # QB: 1
Revenue Correlation: 99.49 | Revenue CAGR: 18.79% | SUE: -1.23 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.80 | Chg30d=+0.053 | Revisions Net=+2 | Analysts=5
EPS current Year (2026-12-31): EPS=7.48 | Chg30d=+0.259 | Revisions Net=+2 | Growth EPS=+13.9% | Growth Revenue=+14.2%
EPS next Year (2027-12-31): EPS=8.22 | Chg30d=+0.234 | Revisions Net=+2 | Growth EPS=+9.9% | Growth Revenue=+9.5%